ASTRANA HEALTH INC (ASTH) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ASTH • US03763A2078

21.1 USD
-0.61 (-2.81%)
At close: Feb 6, 2026
21.1 USD
0 (0%)
After Hours: 2/6/2026, 8:18:26 PM
Fundamental Rating

4

ASTH gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 102 industry peers in the Health Care Providers & Services industry. There are concerns on the financial health of ASTH while its profitability can be described as average. ASTH is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year ASTH was profitable.
  • In the past year ASTH had a positive cash flow from operations.
  • Each year in the past 5 years ASTH has been profitable.
  • In the past 5 years ASTH always reported a positive cash flow from operatings.
ASTH Yearly Net Income VS EBIT VS OCF VS FCFASTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

1.2 Ratios

  • With a Return On Assets value of 0.43%, ASTH perfoms like the industry average, outperforming 50.98% of the companies in the same industry.
  • The Return On Equity of ASTH (1.23%) is comparable to the rest of the industry.
  • The Return On Invested Capital of ASTH (2.95%) is comparable to the rest of the industry.
  • The Average Return On Invested Capital over the past 3 years for ASTH is below the industry average of 9.16%.
  • The 3 year average ROIC (7.07%) for ASTH is well above the current ROIC(2.95%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 0.43%
ROE 1.23%
ROIC 2.95%
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
ASTH Yearly ROA, ROE, ROICASTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

  • The Profit Margin of ASTH (0.33%) is comparable to the rest of the industry.
  • In the last couple of years the Profit Margin of ASTH has declined.
  • ASTH has a Operating Margin (2.59%) which is comparable to the rest of the industry.
  • In the last couple of years the Operating Margin of ASTH has declined.
  • Looking at the Gross Margin, with a value of 10.25%, ASTH is doing worse than 72.55% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ASTH has declined.
Industry RankSector Rank
OM 2.59%
PM (TTM) 0.33%
GM 10.25%
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
ASTH Yearly Profit, Operating, Gross MarginsASTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 5 10 15 20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • ASTH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • ASTH has more shares outstanding than it did 1 year ago.
  • ASTH has a worse debt/assets ratio than last year.
ASTH Yearly Shares OutstandingASTH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M
ASTH Yearly Total Debt VS Total AssetsASTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 2.18 indicates that ASTH is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • The Altman-Z score of ASTH (2.18) is comparable to the rest of the industry.
  • ASTH has a debt to FCF ratio of 10.83. This is a negative value and a sign of low solvency as ASTH would need 10.83 years to pay back of all of its debts.
  • With a Debt to FCF ratio value of 10.83, ASTH perfoms like the industry average, outperforming 43.14% of the companies in the same industry.
  • A Debt/Equity ratio of 1.29 is on the high side and indicates that ASTH has dependencies on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 1.29, ASTH is doing worse than 64.71% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.29
Debt/FCF 10.83
Altman-Z 2.18
ROIC/WACC0.34
WACC8.65%
ASTH Yearly LT Debt VS Equity VS FCFASTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 1.40 indicates that ASTH should not have too much problems paying its short term obligations.
  • The Current ratio of ASTH (1.40) is comparable to the rest of the industry.
  • A Quick Ratio of 1.40 indicates that ASTH should not have too much problems paying its short term obligations.
  • ASTH's Quick ratio of 1.40 is in line compared to the rest of the industry. ASTH outperforms 58.82% of its industry peers.
Industry RankSector Rank
Current Ratio 1.4
Quick Ratio 1.4
ASTH Yearly Current Assets VS Current LiabilitesASTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • ASTH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -85.38%.
  • Measured over the past years, ASTH shows a quite strong growth in Earnings Per Share. The EPS has been growing by 19.19% on average per year.
  • Looking at the last year, ASTH shows a very strong growth in Revenue. The Revenue has grown by 68.17%.
  • The Revenue has been growing by 38.01% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-85.38%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-96.97%
Revenue 1Y (TTM)68.17%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%99.71%

3.2 Future

  • Based on estimates for the next years, ASTH will show a very strong growth in Earnings Per Share. The EPS will grow by 31.87% on average per year.
  • ASTH is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 18.29% yearly.
EPS Next Y-43.43%
EPS Next 2Y19.69%
EPS Next 3Y29.02%
EPS Next 5Y31.87%
Revenue Next Year59.13%
Revenue Next 2Y41.37%
Revenue Next 3Y30.62%
Revenue Next 5Y18.29%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ASTH Yearly Revenue VS EstimatesASTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B 4B 5B
ASTH Yearly EPS VS EstimatesASTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 111.05 indicates a quite expensive valuation of ASTH.
  • The rest of the industry has a similar Price/Earnings ratio as ASTH.
  • Compared to an average S&P500 Price/Earnings ratio of 27.92, ASTH is valued quite expensively.
  • A Price/Forward Earnings ratio of 16.55 indicates a correct valuation of ASTH.
  • ASTH's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. ASTH is cheaper than 72.55% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 27.78. ASTH is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 111.05
Fwd PE 16.55
ASTH Price Earnings VS Forward Price EarningsASTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • The rest of the industry has a similar Enterprise Value to EBITDA ratio as ASTH.
  • ASTH's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ASTH is cheaper than 82.35% of the companies in the same industry.
Industry RankSector Rank
P/FCF 10.92
EV/EBITDA 14.86
ASTH Per share dataASTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ASTH's earnings are expected to grow with 29.02% in the coming years.
PEG (NY)N/A
PEG (5Y)5.79
EPS Next 2Y19.69%
EPS Next 3Y29.02%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ASTH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ASTRANA HEALTH INC

NASDAQ:ASTH (2/6/2026, 8:18:26 PM)

After market: 21.1 0 (0%)

21.1

-0.61 (-2.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-06
Earnings (Next)03-02
Inst Owners55.03%
Inst Owner ChangeN/A
Ins Owners9.86%
Ins Owner Change0.8%
Market Cap1.06B
Revenue(TTM)2.90B
Net Income(TTM)9.54M
Analysts84.71
Price Target37.63 (78.34%)
Short Float %6.55%
Short Ratio4.73
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.09
Dividend Growth(5Y)N/A
DP86.52%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-73.24%
Min EPS beat(2)-97.78%
Max EPS beat(2)-48.7%
EPS beat(4)0
Avg EPS beat(4)-104%
Min EPS beat(4)-225.16%
Max EPS beat(4)-44.39%
EPS beat(8)4
Avg EPS beat(8)-42.64%
EPS beat(12)7
Avg EPS beat(12)-21.5%
EPS beat(16)10
Avg EPS beat(16)-9.93%
Revenue beat(2)1
Avg Revenue beat(2)-0.53%
Min Revenue beat(2)-1.62%
Max Revenue beat(2)0.57%
Revenue beat(4)2
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-3.56%
Max Revenue beat(4)5.66%
Revenue beat(8)5
Avg Revenue beat(8)0.99%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.06%
PT rev (3m)-18.02%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-75.42%
EPS NY rev (1m)0%
EPS NY rev (3m)-58.79%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.38%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.5%
Valuation
Industry RankSector Rank
PE 111.05
Fwd PE 16.55
P/S 0.37
P/FCF 10.92
P/OCF 9.93
P/B 1.36
P/tB N/A
EV/EBITDA 14.86
EPS(TTM)0.19
EY0.9%
EPS(NY)1.27
Fwd EY6.04%
FCF(TTM)1.93
FCFY9.16%
OCF(TTM)2.12
OCFY10.07%
SpS57.74
BVpS15.46
TBVpS-7.43
PEG (NY)N/A
PEG (5Y)5.79
Graham Number8.13
Profitability
Industry RankSector Rank
ROA 0.43%
ROE 1.23%
ROCE 4.68%
ROIC 2.95%
ROICexc 4.15%
ROICexgc N/A
OM 2.59%
PM (TTM) 0.33%
GM 10.25%
FCFM 3.35%
ROA(3y)4.79%
ROA(5y)5.42%
ROE(3y)8.09%
ROE(5y)10.17%
ROIC(3y)7.07%
ROIC(5y)7.37%
ROICexc(3y)11.13%
ROICexc(5y)11.73%
ROICexgc(3y)50.18%
ROICexgc(5y)49.73%
ROCE(3y)11.21%
ROCE(5y)11.68%
ROICexgc growth 3Y-13.47%
ROICexgc growth 5YN/A
ROICexc growth 3Y-16.27%
ROICexc growth 5YN/A
OM growth 3Y-29.78%
OM growth 5YN/A
PM growth 3Y-38.02%
PM growth 5YN/A
GM growth 3Y-16.57%
GM growth 5YN/A
F-Score3
Asset Turnover1.29
Health
Industry RankSector Rank
Debt/Equity 1.29
Debt/FCF 10.83
Debt/EBITDA 8.9
Cap/Depr 25.55%
Cap/Sales 0.33%
Interest Coverage 2.01
Cash Conversion 94.59%
Profit Quality 1016.69%
Current Ratio 1.4
Quick Ratio 1.4
Altman-Z 2.18
F-Score3
WACC8.65%
ROIC/WACC0.34
Cap/Depr(3y)106.76%
Cap/Depr(5y)87.27%
Cap/Sales(3y)1.49%
Cap/Sales(5y)1.42%
Profit Quality(3y)99.59%
Profit Quality(5y)98.35%
High Growth Momentum
Growth
EPS 1Y (TTM)-85.38%
EPS 3Y-17.24%
EPS 5Y19.19%
EPS Q2Q%-96.97%
EPS Next Y-43.43%
EPS Next 2Y19.69%
EPS Next 3Y29.02%
EPS Next 5Y31.87%
Revenue 1Y (TTM)68.17%
Revenue growth 3Y38.01%
Revenue growth 5YN/A
Sales Q2Q%99.71%
Revenue Next Year59.13%
Revenue Next 2Y41.37%
Revenue Next 3Y30.62%
Revenue Next 5Y18.29%
EBIT growth 1Y-11.33%
EBIT growth 3Y-3.09%
EBIT growth 5YN/A
EBIT Next Year101.88%
EBIT Next 3Y45.68%
EBIT Next 5Y30.45%
FCF growth 1Y11.26%
FCF growth 3Y-4.75%
FCF growth 5YN/A
OCF growth 1Y-23.49%
OCF growth 3Y-9.46%
OCF growth 5YN/A

ASTRANA HEALTH INC / ASTH FAQ

Can you provide the ChartMill fundamental rating for ASTRANA HEALTH INC?

ChartMill assigns a fundamental rating of 4 / 10 to ASTH.


What is the valuation status of ASTRANA HEALTH INC (ASTH) stock?

ChartMill assigns a valuation rating of 4 / 10 to ASTRANA HEALTH INC (ASTH). This can be considered as Fairly Valued.


How profitable is ASTRANA HEALTH INC (ASTH) stock?

ASTRANA HEALTH INC (ASTH) has a profitability rating of 4 / 10.


What is the valuation of ASTRANA HEALTH INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ASTRANA HEALTH INC (ASTH) is 111.05 and the Price/Book (PB) ratio is 1.36.


Can you provide the financial health for ASTH stock?

The financial health rating of ASTRANA HEALTH INC (ASTH) is 3 / 10.